BIOMARIN PHARMACEUTICAL INC (BMRN): debt financing — BioMarin completes $4.8B acquisition of Amicus Therapeutics; adds Galafold, Pombiliti+Opfolda

BIOMARIN PHARMACEUTICAL INC

Acquired Amicus for $14.50/share in cash; total equity value ~$4.8B.
Adds Galafold (Fabry), Pombiliti+Opfolda (Pompe) and DMX-200 (FSGS) to commercial portfolio.
Financed via $2.8B in new term loans ($2.0B Term B, $800M Term A) and 2034 notes.
Expects to provide updated FY2026 guidance on May 4 earnings call.

item 1.01 item 2.03 item 2.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

BIOMARIN PHARMACEUTICAL INC incurred credit facility of $2.0 billion senior secured term loan "B" facility, $800.0 million senior secured term loan "A" facility, and $600.0 mil with Citibank, N.A., as administrative agent and collateral agent at Term SOFR plus an applicable margin; for Term B Loans, 1.75% per annum for Term maturing Term Loan B Facility matures on seventh anniversary of Closing Date; Term Loan A Facility and Revolving Facility each mature on fifth anniversary of Closing Dat.

Instrument: credit facility
Principal: $2.0 billion senior secured term loan "B" facility, $800.0 million senior secured term loan "A" facility, and $600.0 mil
Counterparty: Citibank, N.A., as administrative agent and collateral agent
Rate: Term SOFR plus an applicable margin; for Term B Loans, 1.75% per annum for Term
Maturity: Term Loan B Facility matures on seventh anniversary of Closing Date; Term Loan A Facility and Revolving Facility each mature on fifth anniversary of Closing Dat
Event: incurrence

Exact text from the filing

as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectively). The Credit Agreement provides for a $2.0 billion senior secured term loan “B” facility (the “ Term Loan B Facility ” and the loans thereunder, the “ Term B Loans ”), a $800.0 million senior secured term loan “A” facility (the “

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BIOMARIN PHARMACEUTICAL INC entered into Merger Agreement with Amicus valued at Amicus merged with and into Merger Sub with Amicus continuing as the surviving corporation and as a (effective 2026-04-27).

Action: entry
Agreement: merger
Counterparty: Amicus
Value: Amicus merged with and into Merger Sub with Amicus continuing as the surviving corporation and as a
Effective: 2026-04-27

Exact text from the filing

ursuant to the terms of the Merger Agreement, Amicus merged with and into Merger Sub (the “ Merger ”) with Amicus continuing as the surviving corporation and as a wholly owned subsidiary of BioMarin.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-26-179243

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.